four pages for each - )) ...................... 9 Resources ........................................................................................................................................... 22 Research Plan 23 Introduction to RevisedApplication (Not to exceed 3 pages) .................................................................................................................. Introduction to SupplementalApplication (Not to exceed one page) ....................................................................................................... 23 A.
Specific Aims .. .......................................................................... _'1"""""""" ......................................................................................... J"""""""""""""""" 24 B. Backgroundand Significance.................................................... """"""""""""""""""""""""t""""""""....................................................................................... t'"""""""" 26 C. PreliminaryStudies/ProgressReport/ _;=,.(Items A-D: not to exceed 25 pages*) .._ Phase I ProgressReport (SBIRISTTR Phase II ONLY) I SBIFUSTTRPhase/: Items A.D limitedto 15 pages. I D, Research Designand Methods................................................. _ .......................................................................................... 34 E. Human Subjects........................................................................................................................................................................... 46 Protectionof Human Subjects(Required if Item 4 on the Face Page is marked """"""""Yes"""""""") Inclusionof Women (Required if Item4 on the Face Page is marked""""""""Yes"""""""") .......................................................................... Inclusion of Minorities(Required ir Item 4 on the Face Page is marked """"""""Yes"""""""") ........................................................................ Inclusionof Children(Required if Item 4 on the Face Page is marked =Yes"""""""").......................................................................... Data and SafetyMonitoringPlan (Required if Item4 on the Face Page is marked """"""""Yes"""""""" anda Phase I, I1,or Ill clinical tdalis proposed................................................................................................................................................................. F. VertebrateAnimals....................................................................................................................................................................... 46 G. LiteratureCited............................................................................................................................................................................. 46 H. Consortium/ContractuaAl rrangements ........................................................................................................................................ 51 I. Consultants.................................................................................................................................................................................. 51 J. Product Development Plan (SBIR/STTR Phase II and Fast-Track ONLY) .................................................................................. Checklist ............................................................................................................................................. 52 Check if Appendix (Five collatedsets. No page numbetfngnecessary forAppendix.) Appendixis Included AppendicesNO T PERMITTED for Phase I SB/R/STTR unlessspecilfcaliysolicited. Number of publicationsand manuscriptsacceptedfor publication (not to exceed 10) 10 Other items (list): 1. Color illustrations from the grant application 2. Movies - intravital videomicroscopy supplement

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK052783-09
Application #
7172650
Study Section
General Medicine B Study Section (GMB)
Program Officer
Maric-Bilkan, Christine
Project Start
1997-08-01
Project End
2007-12-31
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
9
Fiscal Year
2007
Total Cost
$348,718
Indirect Cost
Name
New York Medical College
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041907486
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Matsumoto, Kei; Xavier, Sandhya; Chen, Jun et al. (2017) Instructive Role of the Microenvironment in Preventing Renal Fibrosis. Stem Cells Transl Med 6:992-1005
Song, J W; Zullo, J A; Liveris, D et al. (2017) Therapeutic Restoration of Endothelial Glycocalyx in Sepsis. J Pharmacol Exp Ther 361:115-121
Lipphardt, Mark; Song, Jong W; Matsumoto, Kei et al. (2017) The third path of tubulointerstitial fibrosis: aberrant endothelial secretome. Kidney Int 92:558-568
Kida, Yujiro; Zullo, Joseph A; Goligorsky, Michael S (2016) Endothelial sirtuin 1 inactivation enhances capillary rarefaction and fibrosis following kidney injury through Notch activation. Biochem Biophys Res Commun 478:1074-9
Zullo, Joseph A; Fan, Jie; Azar, Tala T et al. (2016) Exocytosis of Endothelial Lysosome-Related Organelles Hair-Triggers a Patchy Loss of Glycocalyx at the Onset of Sepsis. Am J Pathol 186:248-58
Lin, Chi Hua Sarah; Chen, Jun; Zhang, Zhongtao et al. (2016) Endostatin and transglutaminase 2 are involved inĀ fibrosis of the aging kidney. Kidney Int 89:1281-92
Kida, Yujiro; Goligorsky, Michael S (2016) Sirtuins, Cell Senescence, and Vascular Aging. Can J Cardiol 32:634-41
Goligorsky, M S; Hirschi, K (2016) Stress-Induced Premature Senescence of Endothelial and Endothelial Progenitor Cells. Adv Pharmacol 77:281-306
Xavier, Sandhya; Vasko, Radovan; Matsumoto, Kei et al. (2015) Curtailing endothelial TGF-? signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. J Am Soc Nephrol 26:817-29
Rabadi, May M; Xavier, Sandhya; Vasko, Radovan et al. (2015) High-mobility group box 1 is a novel deacetylation target of Sirtuin1. Kidney Int 87:95-108

Showing the most recent 10 out of 96 publications